Previous Close | 12.18 |
Open | 12.32 |
Bid | 12.30 x 1300 |
Ask | 12.34 x 1800 |
Day's Range | 12.24 - 12.72 |
52 Week Range | 6.18 - 27.96 |
Volume | |
Avg. Volume | 5,176,811 |
Market Cap | 2.003B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.30 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.23 |
Subscribe to Yahoo Finance Plus to view Fair Value for IOVA
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter and first half 2022 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive O
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 4, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference call, please register at https://register.vevent.com/register/BI2